<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01043445</url>
  </required_header>
  <id_info>
    <org_study_id>GPR119</org_study_id>
    <nct_id>NCT01043445</nct_id>
  </id_info>
  <brief_title>-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans.</brief_title>
  <official_title>G Protein-coupled Receptor in the Intestine (GPR 119) Stimulated GLP-1 Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Glostrup University Hospital, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the impact of different ligands of GPR 119 (a G
      protein-coupled receptor in the intestine) on the secretion of the incretin hormones, GLP-1
      and GIP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We have found a new ligand for the GPR 119 receptor. This study evaluate the impact of this
      ligand on the incretion hormone responses, beta cell function and gall bladder function in
      healthy young men.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of this newly discovered GPR 119 agonist on gut hormone responses, in particular GLP-1 in response of the different meals administered to the subjects</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose homeostasis, gall bladder contraction in response of the different meals administered to the subjects</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>GPR119 agonist, 2-oleoyl glycerol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-oleoyl glycerol; 2g. and vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oleic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oleic acid; 3.2g and vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 ml. of glycerol and 5 ml 96% ethanol</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GPR 119 agonist, 2-oleyl glycerol</intervention_name>
    <description>Emulgation, 50 ml. containing 2g 2OG</description>
    <arm_group_label>GPR119 agonist, 2-oleoyl glycerol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oleic acid</intervention_name>
    <description>Emulgation, 50 ml. containing 1.54g of oleic acid</description>
    <arm_group_label>Oleic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol</description>
    <arm_group_label>GPR119 agonist, 2-oleoyl glycerol</arm_group_label>
    <arm_group_label>Oleic acid</arm_group_label>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy caucasians v- Normal OGTT (75 g of glucose) according to WHO's criteria

          -  Normal hemoglobin

          -  Informed consent

        Exclusion Criteria:

          -  Liver disease (ALAT&gt; 2x normal level)

          -  Nephropathy (s-creatinin &gt;130 microM or albuminuria)

          -  Relatives with type 2 diabetes
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katrine B Hansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glostrup Hospital, University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Filip K Knop, MD, Ph.d</last_name>
    <role>Study Director</role>
    <affiliation>Gentofte Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harald S Hansen, professor</last_name>
    <role>Study Director</role>
    <affiliation>Farmaceutical Faculty, University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens J Holst, MD;DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Biomedical Science, University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Physiology, Glostrup Hospital</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2009</study_first_submitted>
  <study_first_submitted_qc>January 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2010</study_first_posted>
  <last_update_submitted>October 8, 2014</last_update_submitted>
  <last_update_submitted_qc>October 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Glostrup University Hospital, Copenhagen</investigator_affiliation>
    <investigator_full_name>Katrine Bagge Hansen</investigator_full_name>
    <investigator_title>MD, Ph.d</investigator_title>
  </responsible_party>
  <keyword>GPR 119</keyword>
  <keyword>GLP-1 secretion</keyword>
  <keyword>2-oleoyl-glycerol</keyword>
  <keyword>Dietary supplementation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycerol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

